The concept of the development of inflammatory bowel diseases as a consequence of intestinal metabolic dysbiosis-Reference-Cited by-同舟云学术

The concept of the development of inflammatory bowel diseases as a consequence of intestinal metabolic dysbiosis

Published:2024-01-17 Issue:9 Volume: Page:162-167
ISSN:1682-8658
Container-title:Experimental and Clinical Gastroenterology
language:
Short-container-title:jour

Author:

Tarasova L. V.¹,Tsyganova Yu. V.¹^ORCID,Pavlova S. I.¹,Kucherova N. Y.¹

Affiliation:

1. Chuvash State University named after I. N. Ulyanova

Abstract

The article discusses the high relevance of the problem of inflammatory bowel diseases (IBD). First of all, attention is drawn to the annual increase in the incidence of ulcerative colitis and Crohn’s disease. Factors that can influence the development of IBD are assessed. A diagram of the pathogenetic cascade of dysbiotic disorders is presented, manifested by an increase in the blood serum of metabolic products of the intestinal microflora, microvascular, metabolic and immune changes leading to the triggering of inflammation in the intestinal wall.

Publisher

LLC Global Media Technology

Reference42 articles.

1. Knyazev O.V., Shkurko T. V., Fadeyeva N. A., Bakulin I. G., Bordin D. S. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;(3):4-12. (In Russ.)@@ Knyazev O. V., Shkurko T. V., Fadeeva N. A., Bakulin I. G., Bordin D. S. Epidemiologiya khronicheskikh vospalitel'nykh zabolevanii kishechnika. Vchera, segodnya, zavtra. Eksperimental'naya i klinicheskaya gastroenterologiya. 2017;(3):4-12.

2. Veselov A.V., Belousova E. A., Bakulin I. G. [et al.]. Assessment of the economic burden and the current state of the organization of drug provision for patients with immunoinflammatory diseases (using the example of ulcerative colitis and Crohn’s disease) in the Russian Federation. Problems of social hygiene, health care and history of medicine. 2020;28(special issue):1137-1145. (in Russ.) doi: 10.32687/0869-866X-2020-28-s2-1137-1145E.@@ Veselov A. V., Belousova E. A., Bakulin I. G. i soavt. Otsenka ekonomicheskogo bremeni i tekushchego sostoyaniya organizatsii lekarstvennogo obespecheniya patsientov s immunovospalitel'nymi zabolevaniyami (na primere yazvennogo kolita i bolezni Krona) v Rossiiskoi Federatsii. Problemy sotsial'noi gigieny, zdravookhraneniya i istorii meditsiny. 2020;28(spetsvypusk):1137-1145. doi: 10.32687/0869-866X-2020-28-s2-1137-1145E.

3. Valuyskikh Yu., Svetlova I. O., Kurilovich S. A. et al. Clinical and genetic aspects of inflammatory bowel diseases.Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2008; 18(6): 68-74. (in Russ.)@@ Valuiskikh Yu., Svetlova I. O., Kurilovich S. A. i soavt. Kliniko-geneticheskie aspekty vospalitel'nykh zabolevanii kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii i koloproktologii. 2008; 18(6): 68-74.

4. Syed U., Subramanian A., Wraith D. C. et al. Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. BMC Med. 2023;(21):363. doi: 10.1186/s12916-023-03049-5.

5. Räisänen L., Viljakainen H., Kolho K-L. Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases. Front. Pediatr.2023;(11):1157547. doi: 10.3389/fped. 2023.1157547.